I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Terrance Coyne Biography and Net Worth

CFO of Royalty Pharma

Terrance Coyne joined RP Management in 2010. He serves as our Executive Vice President & Chief Financial Officer. Previously, Mr. Coyne was a biotechnology equity research associate, a senior analyst at JP Morgan and a biotechnology equity research associate at Rodman & Renshaw. Mr. Coyne began his career at Wyeth Pharmaceuticals. Mr. Coyne received a B.S. in business administration from La Salle University and an M.B.A. from La Salle University. Provided by Tagnifi.

What is Terrance P. Coyne's net worth?: The estimated net worth of Terrance P. Coyne is at least $20.62 million as of August 9th, 2023. Mr. Coyne owns 827,500 shares of Royalty Pharma stock worth more than $20,621,300 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Coyne may own. Learn More about Terrance P. Coyne's net worth.
How do I contact Terrance P. Coyne?: The corporate mailing address for Mr. Coyne and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Terrance P. Coyne's contact information.
Has Terrance P. Coyne been buying or selling shares of Royalty Pharma?: Terrance P. Coyne has not been actively trading shares of Royalty Pharma during the last ninety days. Most recently, Terrance P. Coyne sold 37,500 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $30.72, for a transaction totalling $1,152,000.00. Following the completion of the sale, the chief financial officer now directly owns 827,500 shares of the company's stock, valued at $25,420,800. Learn More on Terrance P. Coyne's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 312,631 shares worth more than $8,860,323.39. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

Terrance P. Coyne Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2023	Sell	37,500	$30.72	$1,152,000.00	827,500
7/12/2023	Sell	37,500	$31.07	$1,165,125.00	902,500
11/8/2022	Sell	24,500	$43.47	$1,065,015.00	940,000
11/2/2022	Sell	5,500	$43.06	$236,830.00	964,500
8/1/2022	Sell	30,000	$43.19	$1,295,700.00	970,000
3/2/2021	Sell	100,000	$46.94	$4,694,000.00	1,500
6/18/2020	Buy	1,500	$28.00	$42,000.00	1,500

Terrance P. Coyne Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $24.92

$24.32

$25.00

50 Day Range

MA: $26.43

$24.28

$28.22

2 Week Range

Now: $24.92

$24.05

$31.66

Volume

7,574,639 shs

Average Volume

2,691,117 shs

Market Capitalization

$14.68 billion

P/E Ratio

12.91

Dividend Yield

3.43%

Beta

0.46

I was wrong. Dead wrong.

From Porter & Company | Ad